Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
{ "Aria CV Pulmonary Hypertension System for Pulmonary Hypertension", "This study is testing a device called the Aria CV Pulmonary Hypertension System for adults with pulmonary hypertension (high blood pressure in the lungs) and right heart dysfunction (when the right side of your heart isn't pumping well). The device is for people who are still having symptoms even after trying other treatments. The main goal of this study is to see if the Aria CV Pulmonary Hypertension System is safe for patients. To join, you must be at least 18 years old and have specific measurements of your lung pressure and heart function. The study plans to enroll up to 30 patients, but the current status of enrollment is unclear.", "design": "This is an early study that will test the device in up to 30 patients at multiple centers. It is a single-arm study, meaning everyone receives the same treatment.", "commitments": "If you participate, you will have the device implanted and attend follow-up visits for about two years. These visits occur at various times, including shortly after the procedure and then regularly for up to 24 months.", "compensation": "Not stated in the trial record.", "follow_up": "Participants will be followed for up to 24 months after the device is implanted to assess its safety and performance.", }
- Study design
- Not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
At a glance
Conditions
Where it's being run
12 sites across 8 statesStudy leadership
- Ashwin Ravichandran, M.D. · PRINCIPAL_INVESTIGATOR · Ascension Health
- Jim White, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · University of Rochester
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Primary Safety Endpoint is the incidence of investigational device- or procedure-related serious adverse events (SAEs).30 days post-implant
The primary safety endpoint is the incidence of investigational device- or procedure-related serious adverse events through 30 days post-index procedure.